| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
The molecular targets of (+)-Isolariciresinol include enzymes involved in fatty acid and prostaglandin synthesis, which it blocks. It has antimicrobial activity against human pathogens. It inhibits CYP2D6 with an IC₅₀ of 97.7 µM. It inhibits LPS-induced NO and ROS productions in RAW 264.7 cells. These multiple targets contribute to its diverse biological activities.
|
|---|---|
| ln Vitro |
In vitro, (+)-Isolariciresinol exhibits potent antioxidant activities on DPPH and ABTS radical scavenging assays, with an ABTS IC₅₀ of 19.4 µM. It shows significant inhibitory activity on LPS-induced NO and ROS productions in RAW 264.7 cells. It inhibits the production of fatty acids and prostaglandins by blocking the enzyme complex involved in their synthesis. It has antimicrobial activity against human pathogens and inhibits CYP2D6 (IC₅₀ 97.7 µM).
|
| ln Vivo |
Specific in vivo activity data for (+)-Isolariciresinol are not available in the consulted sources. Its in vitro anti-inflammatory and antioxidant activities suggest potential in vivo efficacy in models of inflammation, oxidative stress, and rheumatism. Its antimicrobial activity suggests potential for infectious disease research. However, no specific in vivo studies have been reported.
|
| Enzyme Assay |
Typical in vitro assays for (+)-Isolariciresinol include DPPH and ABTS radical scavenging assays, where the compound is incubated with radical solutions and absorbance is measured at specific wavelengths. Anti-inflammatory assays measure NO production by Griess assay and ROS production by fluorescent probes in LPS-stimulated RAW 264.7 cells. Antimicrobial activity is assessed by broth microdilution for MIC determination. CYP2D6 inhibition is measured by fluorometric assays.
|
| Cell Assay |
Cellular assays for (+)-Isolariciresinol typically involve treating RAW 264.7 macrophages with the compound at concentrations ranging from 1-100 µM for 24-48 hours, followed by LPS stimulation. NO levels are measured by Griess assay. ROS levels are measured using fluorescent probes. Inflammatory markers such as TNF-α and IL-6 are measured by ELISA. These cell-based systems allow for detailed analysis of the compound's anti-inflammatory and antioxidant mechanisms.
|
| Animal Protocol |
In vivo animal experiments for (+)-Isolariciresinol are not detailed in the available literature. For rheumatism studies, typical animal models include collagen-induced arthritis in mice. For anti-inflammatory studies, models such as carrageenan-induced paw edema are used. For antimicrobial studies, infection models are used. However, such studies have not been reported for this specific compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for (+)-Isolariciresinol are limited. As a lignan with a molecular weight of 360.40 g/mol, it would be expected to have moderate oral bioavailability. Lignans are typically metabolized by gut microbiota and hepatic enzymes. However, detailed ADME parameters are not available in the consulted sources.
|
| Toxicity/Toxicokinetics |
Toxicological data for (+)-Isolariciresinol are limited. As a natural lignan, it is generally considered to have low toxicity. It is found in Radix Isatidis, a plant used in traditional medicine. However, comprehensive toxicological studies have not been reported. Standard laboratory safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
(+)-Isolarisinol is a lignan with the structure 5,6,7,8-tetrahydronaphth-2-ol, substituted with hydroxymethyl groups at positions 6 and 7, a methoxy group at position 3, and a 4-hydroxy-3-methoxyphenyl group at position 8. It has been isolated from the roots of Rubia yunnanensis. It is a plant metabolite. It is a lignan, polyphenol, primary alcohol, and a guaiacol compound. It has also been reported to be found in Tsuga chinensis, Salacia chinensis, and several other organisms with relevant data. See also: Acai berry pulp (partial).
(+)-Isolariciresinol ((+)-Cyclolariciresinol) is a lignan with antioxidant (ABTS IC₅₀ 19.4 µM), anti-inflammatory, antimicrobial, and CYP2D6 inhibitory activities. It inhibits fatty acid and prostaglandin synthesis and is applicable in rheumatism studies. It is extracted from Radix Isatidis. It is a research compound for studying inflammation, oxidative stress, rheumatism, and infectious diseases. It is not approved for any clinical indication. |
| Molecular Formula |
C20H24O6
|
|---|---|
| Molecular Weight |
360.40
|
| Exact Mass |
360.157
|
| CAS # |
548-29-8
|
| PubChem CID |
160521
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
584.1±50.0 °C at 760 mmHg
|
| Flash Point |
307.1±30.1 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.603
|
| LogP |
1.64
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
26
|
| Complexity |
446
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
COC1=C(C=C2[C@@H]([C@H]([C@@H](CC2=C1)CO)CO)C3=CC(=C(C=C3)O)OC)O
|
| InChi Key |
OGFXBIXJCWAUCH-KPHUOKFYSA-N
|
| InChi Code |
InChI=1S/C20H24O6/c1-25-18-6-11(3-4-16(18)23)20-14-8-17(24)19(26-2)7-12(14)5-13(9-21)15(20)10-22/h3-4,6-8,13,15,20-24H,5,9-10H2,1-2H3/t13-,15-,20-/m0/s1
|
| Chemical Name |
(6R,7R,8S)-8-(4-hydroxy-3-methoxyphenyl)-6,7-bis(hydroxymethyl)-3-methoxy-5,6,7,8-tetrahydronaphthalen-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7747 mL | 13.8735 mL | 27.7469 mL | |
| 5 mM | 0.5549 mL | 2.7747 mL | 5.5494 mL | |
| 10 mM | 0.2775 mL | 1.3873 mL | 2.7747 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
